Condition: Non-alcoholic Fatty Liver Disease · Sponsor: Beijing Municipal Administration of Hospitals
Collect confirmed cases of NAFLD patients and enroll them in the study. Select patients with NASH and fibrosis stage F2-4 confirmed by liver biopsy, and collect clinical and pathological data for relevant evaluation and definition. Establish a NASH "fibrosis reversal" pathological evaluation system, based on a new reversal standard, establish non-invasive alternative indicators, and observe indicators.
This description comes directly from the study's public registry record.
Minghui Li · +8613693259096 · wuhm2000@sina.com
Weihua Cao · +8618811333129 · weihuacaohappy@163.com
Always discuss trial participation with your own doctor first.
| Beijing Ditan Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06707129